Treatment Outcomes of Postmenopausal Osteoporosis in Patients with Stable Hypothyroidism: A 5-Year Follow-up Retrospective Study

Abstract

The aim of this study was to evaluate the effects of hypothyroidism on the treatment outcomes of the postmenopausal osteoporosis (PMOP) treatment. Materials and Methods: A total of 50 patients with hypothyroidism who were also diagnosed with PMOP according to the lumbar and femur neck bone mass density (BMD) evaluation with dual X-ray absorptiometry who did not receive any treatment for PMOP, including calcium and vitamin D, were included in the study. The control group consisted of 47 patients with PMOP but had no comorbidity. Demographic features including age, height, weight, occupation, the level of education, menarche and menopause age, clothing style, daily calcium intake, tobacco and/or alcohol consumption, daily physical activity level, personal (or maternal) history of fragility fracture, and duration of hypothyroidism were recorded. Biochemical parameters including the BMD scores, calcium, phosphate, alkaline phosphatase, parathormone, calcidiol, osteocalcine, urine calcium, phosphate levels, and creatinine clearance were also recorded. Patients were treated with bisphosphonate, calcium, and vitamin D, and same parameters were evaluated at the end of the first and fifth year. Results: The average age of all individuals was 58.25±8.89 years, and the average duration of hypothyroidism diagnosis was 4.00 years. The demographic features and biochemical parameters before the PMOP treatment were not different between the patient and the control groups (p>0.005). The BMD scores of both groups were significantly improved at the end of the first and fifth years of the treatment (p<0.005), but the variations of the scores were not different. Conclusion: Hypothyroidism with stable or unstable thyroid functions does not affect the PMOP treatment prognosis in Turkish population.